Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.74 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.74 |
| ▸ | MMP9 | P14780 | 8/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 1/20 | 0.56 |
| ▸ | MMP3 | P08254 | 1/20 | 0.56 |
| ▸ | MMP7 | P09237 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121167 | 1.00 | MMP2 (0.74) | MMP2ADAMTS5MMP9ADAMTS4TSHR | |
| SCHEMBL13890444 | 0.89 | MMP2 (0.74) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3009401 | 0.89 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3009406 | 0.89 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3013315 | 0.89 | MMP2 (0.92) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3890915 | 0.88 | MMP2 (0.76) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3890918 | 0.88 | MMP2 (0.76) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL11704464 | 0.87 | MMP2 (0.71) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL3002038 | 0.87 | MMP2 (0.71) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 | |
| SCHEMBL4164072 | 0.85 | MMP2 (0.73) | MMP2ADAMTS5MMP9ADAMTS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7345095-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER INC | 2007-06-07 | — | — | US | disclosed |
| CN-1938266-A | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER PROD INC (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1747195-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | disclosed |
| US-7163942-B2 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| WO-2005095334-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129349-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | PSEN1, APP, PSEN2 | MMP2 3165/4885ADAMTS5 3348/4885MMP9 3400/4885 |
| US-20050222254-A1 | Sulfonamide compounds for the treatment of neurodegenerative disorders | PSEN1, APP, PSEN2 | MMP2 3078/4885ADAMTS5 3351/4885MMP9 3441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.